TNNT1 accelerates migration, invasion and EMT progression in lung cancer cells.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 23, p. 1749, doi. 10.1111/1759-7714.15400
- By:
- Publication type:
- Article
Works matching IS 17597706 AND DT 2024 AND VI 15 AND IP 23
Results: 7
1
2
The efficacy of almonertinib and anlotinib combination therapy for advanced non‐small‐cell lung cancer patients who continued to experience cancer progression during third‐generation EGFR‐TKI treatment: a retrospective study.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 23, p. 1757, doi. 10.1111/1759-7714.15399
- By:
- Publication type:
- Article
3
The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 23, p. 1764, doi. 10.1111/1759-7714.15401
- By:
- Publication type:
- Article
4
PRPS2‐mediated modulation of the antitumor immune response in lung cancer through CCL2‐mediated tumor‐associated macrophages and myeloid‐derived suppressor cells.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 23, p. 1739, doi. 10.1111/1759-7714.15398
- By:
- Publication type:
- Article
5
Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 23, p. 1772, doi. 10.1111/1759-7714.15395
- By:
- Publication type:
- Article
6
Women patients with small‐cell lung cancer using immunotherapy in a real‐world cohort achieved long‐term survival.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 23, p. 1727, doi. 10.1111/1759-7714.15393
- By:
- Publication type:
- Article
7
Issue Information.
- Published in:
- Thoracic Cancer, 2024, v. 15, n. 23, p. 1725, doi. 10.1111/1759-7714.14966
- Publication type:
- Article